<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report on a hemodialysis (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) patient in whom fatal <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> developed after the administration of nizatidine, a <z:chebi fb="11" ids="18295">histamine</z:chebi> 2 (H2)-receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The patient was a 55-year old Japanese woman and had been on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> for 2 years due to endstage diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The patient had a hemorrhagic <z:hpo ids='HP_0002588'>duodenal ulcer</z:hpo> and had been treated with <z:chebi fb="0" ids="6375">lansoprazole</z:chebi>, a <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi>, for 2 months </plain></SENT>
<SENT sid="3" pm="."><plain>After improvement, lansoprozole was discontinued and she was subsequently treated with nizatidine </plain></SENT>
<SENT sid="4" pm="."><plain>Twelve days after initiation of nizatidine treatment, the patient developed a high-grade <z:hpo ids='HP_0001945'>fever</z:hpo> with symptoms suggestive of upper <z:hpo ids='HP_0011947'>respiratory infection</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Hematological tests showed severe <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, and drug-induced <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> was diagnosed </plain></SENT>
<SENT sid="6" pm="."><plain>Nizatidine was suggested as the causal drug </plain></SENT>
<SENT sid="7" pm="."><plain>Despite intensive therapies, the patient died on the 23rd hospital day from generalized <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Although hematological adverse events have been reported in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> patients receiving <z:chebi fb="0" ids="37961">H2-receptor antagonists</z:chebi>, few studies of fatal <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> associated with these drugs have been reported </plain></SENT>
<SENT sid="9" pm="."><plain>This case emphasized that careful observation is required after the initiation of <z:chebi fb="0" ids="37961">H2-receptor antagonist</z:chebi> treatment in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> patients </plain></SENT>
</text></document>